Measurement of fasting and postprandial plasma
VIP in man

S. J. MITCHELL AND S. R. BLOOM

From the Department of Nuclear Medicine, Thorn Institute of Clinical Science, Middlesex Hospital Medical School, London, and the Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London

SUMMARY A specific radioimmunoassay has been developed capable of detecting 1·5 pmol VIP/l plasma with 95% confidence. The antisera employed reacted most avidly with whole VIP, partly with C terminal, but not with N terminal fragments. In 110 healthy fasting volunteers plasma VIP concentrations were estimated to lie between 0·5 and 21 pmol/l (median 1·7). No significant change was seen after ingestion of a standard test meal.

Vasoactive intestinal peptide (VIP) is a basic polypeptide composed of 28 amino acids (Bodanszky et al., 1973) and shares many homologies with the classical hormones secretin and glucagon (Bodanszky et al., 1973). It was isolated from the hog small intestine by Said and Mutt in 1970 and is widely distributed throughout the intestine in a single major molecular form (Bloom and Bryant 1973). It has recently been found in significant quantities in many other tissues including the central nervous system and has been proposed as a possible neurotransmitter (Bryant et al., 1976). Its range of pharmacological actions includes inhibition of gastric acid production (Barbezat and Grossman, 1971), stimulation of alkaline pancreatic juice flow (Said and Mutt, 1972), stimulation of myocardial contractility (Said and Mutt, 1972), and glycogenolysis (Kerins and Said, 1973). In addition, it causes a significant increase in mucosal cyclic AMP concentration (Schwartz et al., 1974) and small intestinal juice production (Barbezat et al., 1971).

It was first implicated in the Verner-Morrison syndrome after the finding of high circulating levels of VIP as well as large amounts of extractable VIP in the tumours of these patients (Bloom et al., 1973). A sensitive assay for the measurement of plasma levels has been developed to study the physiology and pathology of VIP.

Methods

Antisera to pure porcine VIP were produced in rabbits by multiple subcutaneous injections of 100 nmol/rabbit VIP, conjugated to 50 nmol bovine serum albumin (BSA) by carbodiimide condensation, emulsified in complete Freund’s adjuvant. Boost injections were given at three monthly intervals and antisera harvested between one and two years. Synthetic VIP fragments 1-6, 1-18, 1-22, 7-28, 11-28, and 18-28, pure chicken VIP and an extract of human VIPoma were used to assess antisera binding characteristics.

Incorporation of 0·7-1·1 nmol 125I IMS 30 Amersham (approx 2MCi/mol) into 6 nmol pure porcine VIP in 50 mmol/l acetate buffer at pH 5·0 was achieved by incubating with 22 pmol lactoperoxidase (Sigma milk derived) and 1·8 nmol H2O2 at room temperature for 15 minutes in a total volume of 130 μl. The 125I VIP was purified on CM Sephadex C25 column (1·5 × 30 cm) at 4°C over 36 hours, using 160 mmol/l phosphate buffer at pH 8·5 containing 0·4 mmol/l human albumin (Lister Institute) and 0·4 MKIU/l aprotinin (TrasyloL) as the eluent.

Blood samples were taken with 20 KU/l heparin and 0·5 MKIU/l aprotinin, centrifuged immediately, and the decanted plasma stored at −20°C until assay. The stability of exogenous porcine VIP added to three fresh plasmas (50 pmol/l) was tested by incubation, in presence or absence of aprotinin, at room temperature for between one and 24 hours. Estimations of endogenous VIP content in plasmas.
from four patients with a VIPoma (80 to 450 pmol/l) were compared in two aliquots, one being left at −20°C undisturbed for six months and the other being briefly thawed at 18°C and refrozen on three occasions during this time.

Assay tubes were set up in duplicate, each with 200 μl unknown plasma and 600 μl of 50 mmol/l phosphate buffer, pH 7-0, containing antibody (1:320,000 dilution) and 1 fmol VIP 125I and incubated for four days at 4°C. Separation of bound antibody from free VIP 125I was effected by addition of 26 mg/tube charcoal suspension (Norit GSX, Hopkins & Williams Ltd) in 0-5 ml buffer containing 2-6 mg dextran (Fig. 1). The standard curve was made by addition of varying quantities of a pure natural porcine VIP standard to VIP-free plasma. VIP standards were prepared gravimetrically (Cahn Electrobalance). The VIP was then dissolved in a protein-containing solution (0-14 mol/l lactose, 0-4 mmol/l BSA, 11 mmol/l citric acid, 6 mmol/l cysteine HCl, and 1 MKIU/l aprotinin in 100 mmol/l formic acid), lyophilised in aliquots; sealed in vacuum and stored at −20°C.

Hormone-free plasma was prepared from pooled, freshly collected plasma using specific immunoabsorption with high titre VIP antiserum coupled to cyanogen bromide activated Sepharose beads (Pharmacia Ltd). Six millilitres of VIP antisera (titre 1:64,000) was coupled to 20 ml wet Sepharose beads and used to treat 100 ml plasma (Alford et al., 1977). Very thorough washing of the beads immediately before use prevented contamination of the plasma with any free VIP antibody. The activity of the beads was checked by demonstrating complete removal of 500 pmol/l of added exogenous VIP. The plasma VIP content was unaffected by treatment with Sepharose beads prepared using non-VIP antiserum.

To establish a normal range, plasma samples from 110 healthy fasting volunteers (mean age 29 years, range 18-40 years) were assayed. The plasma VIP response to a test meal (79 g carbohydrate, 28 g protein, and 44 g fat) was tested in a further 10 subjects. Gastrin concentrations were also estimated for reference purposes using a previously described radioimmunoassay system (Russell et al., 1976).

Results

Only 10% of the 200 rabbits immunised over a four year programme produced a significant titre of antibodies to VIP. Of these only two, V9 and V25, were of sufficient affinity to be useful for plasma radioimmunoassay, both being useable at a dilution of 1:400,000 (50% binding point with 1 fmol VIP 125I in 0-8 ml buffer). Binding was reduced to 40% by addition of 7 and 12 pmol/l VIP with antisera V9 and V25 respectively. The displacement by VIP fragments 18-28 and 7-28 is shown in Fig. 2 and the other fragments, chicken and human VIP, in Table 1. While antisera V25 reacts well with C terminal fragments, antisera V9 reacts fully only with whole VIP. Both react equally with human VIP. Neither showed any displacement on addition of 500 nmol/assay tube of glucagon, secretin, gastrin, motilin, cholecystokinin, or gastric inhibitory peptide. Antiserum V9 was used for all assays subsequently both because of its minimal reaction with VIP fragments and its greater sensitivity, allowing changes of 1-5 pmol/l plasma VIP (0-3 fmol/tube) to be distinguished with 95% confidence (Fig. 3).

During iodination approximately 60% of the added 125I reacted with 10% of the VIP. Clear separation of the iodinated tracer from other iodinated products (Fig. 4), including diiodinated VIP and non-iodinated VIP, allowed preparation of a stable monoiiodinated tracer with a specific activity of between 1-6 and 2-0 MCi/mol, identical specific activity values being obtained when calculated either by self displacement or stoichiometrically. Stored at −20°C the label was usable up to four months.

No significant loss of exogenous porcine VIP in the three fresh plasma samples was observed over a
Measurement of fasting and postprandial plasma VIP in man

A four hour period at room temperature in the presence of aprotinin (Table 2). A loss in endogenous VIP content between 20-35% was found after repeated freezing and thawing of the plasma samples from VIPoma patients. The freeze-dried standards were stable (loss less than 5%) for more than three years when tested at regular intervals against freshly prepared porcine VIP standards.

The measured plasma VIP concentrations in 110 normal subjects showed a skew distribution ranging from 0.5 to 21 pmol/l with a mean of 2.1, mode of 1.5 and the median of 1.7 (Fig. 5). No significant rise of VIP was seen after the meal (Fig. 6), unlike the considerable rise in plasma gastrin.

**Table 1  Binding characteristics of antisera V9 and V25 with VIP fragments and other forms of VIP**

<table>
<thead>
<tr>
<th>VIP Type</th>
<th>V9</th>
<th>V25</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-6</td>
<td>&gt;5 x 10^{-8}</td>
<td>&gt;5 x 10^{-8}</td>
</tr>
<tr>
<td>1-18</td>
<td>6 x 10^{-11}</td>
<td>9 x 10^{-11}</td>
</tr>
<tr>
<td>1-22</td>
<td>1 x 10^{-11}</td>
<td>3 x 10^{-11}</td>
</tr>
<tr>
<td>7-28</td>
<td>2 x 10^{-11}</td>
<td>3 x 10^{-11}</td>
</tr>
<tr>
<td>11-28</td>
<td>9 x 10^{-11}</td>
<td>5 x 10^{-11}</td>
</tr>
<tr>
<td>18-28</td>
<td>6 x 10^{-8}</td>
<td>2 x 10^{-11}</td>
</tr>
<tr>
<td>Chicken</td>
<td>&gt;5 x 10^{-11}</td>
<td>&gt;5 x 10^{-11}</td>
</tr>
<tr>
<td>Human (Crude tumour extract)</td>
<td>2 x 10^{-11}</td>
<td>3 x 10^{-11}</td>
</tr>
<tr>
<td>Porcine</td>
<td>5 x 10^{-14}</td>
<td>9 x 10^{-14}</td>
</tr>
</tbody>
</table>

Figures indicate mol/assay tube which cause 50% displacement of porcine VIP from the antibody at normal working dilution and four days incubation. The VIP content of crude human tumour extract is on an arbitrary basis only and is shown solely for comparison of the two antisera.

**Discussion**

In contrast to the other hormonal peptides in the secretin-glucagon group, VIP is only weakly anti-
S. J. Mitchell and S. R. Bloom

Fig. 4 Elution pattern of crude VIP iodination reaction product from CM Sephadex C25 ion exchange column (K15/30). The elution buffer was 0·16 mol/l phosphate at pH 8·5 and was collected in 3 ml fractions run at a rate of 5 ml/h. The iodination product had 100 pmol cold pure porcine VIP added immediately before ion exchange to act as a marker. Non-iodinated VIP measured by radioimmunoassay is shown as dotted lines, while the eluted radioactive product is shown as solid lines, the first peak being $^{125}$I and the second VIP $^{125}$I.

Table 2 Stability of added pure porcine VIP (50 pmol/l) at room temperature in the presence or absence of aprotinin in three fresh plasmas from fasting healthy volunteers

<table>
<thead>
<tr>
<th>Incubation conditions</th>
<th>Mean % loss With aprotinin</th>
<th>Mean % loss Without aprotinin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frozen immediately</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Room temperature (h)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>30</td>
</tr>
<tr>
<td>12</td>
<td>5</td>
<td>40</td>
</tr>
<tr>
<td>24</td>
<td>16</td>
<td>42</td>
</tr>
</tbody>
</table>

genic, which is surprising for such a strongly charged molecule, making difficult the development of high affinity antisera. Iodination, however, presented few problems as VIP has two tyrosine residues. Although possessing no tryptophan, the presence of a methionine residue at position 17 renders VIP susceptible to oxidative damage. Thus the use of a trace iodination technique followed by separation of the pure moniodinated VIP by high resolution ion exchange chromatography not only avoided significant oxidative damage but also gave a uniform iodination.

Fig. 5 Plasma VIP concentrations in 110 healthy fasting subjects.
Fig. 6  Response of plasma radioimmunoassayable gastrin and VIP to ingestion of a standard lunch in 10 healthy volunteers.

Product of high specific activity. When stored in a dilute protein solution at −20°C the label showed little change in binding characteristics over many months.

VIP in plasma samples was readily degraded at room temperature and this could not be completely prevented by addition of aprotinin. Care was therefore taken to deep freeze samples within 15 minutes of venepuncture and to avoid repetitive freezing and thawing. Stability of the VIP standards was ensured by storing them lyophilised in mass-produced single use vials.

Human VIP has not yet been isolated, raising the possibility of a species difference between human and porcine VIP. The variation between chicken and porcine VIP is small, though easily detected by the antisera tested here, however, with alterations in only four amino acids (Nilsson, 1975). Human and porcine VIP migrate in identical positions on gel columns, show parallel dilution curves in radioimmunoassay, and cross-react equally with porcine antisera of varying specificity. It thus seems unlikely that they have significant differences in their amino acid sequence. It was also of interest that when crude extracts of human ileum were subjected to gel chromatography only a single major peak of VIP immunoreactivity was detected (Bryant et al., 1976) thus excluding the possibility of any significant cross-reaction with our assay of any, as yet undiscovered, gut hormonal peptides.

The fasting level of plasma VIP is very low and many normal subjects have concentrations below the individual 95% confidence limit of the assay. In patients with watery diarrhoea resulting from the presence of a VIP-producing tumour, plasma levels are in excess of 50 pmol/l (Bloom, 1978). Therefore with this assay there is no problem in reliably excluding excessive circulating VIP as the cause of active diarrhoea. The reason for the higher values reported by others (Said and Mutt, 1972; Ebeid et al., 1976) is unknown but may relate to greater sensitivity of this assay, which reduces the influence of interference by non-specific plasma effects and also to the low reactivity with VIP fragments. The physiological role of VIP is still unknown and this is emphasised by the failure to find a change in circulating concentrations after a meal. VIP is found in larger quantities in the gut than any other of the gastrointestinal hormonal peptides so far described. It is also found in almost all other tissues of the body and its localisation in neurones of the central nervous system and in fine nerve fibres in the periphery suggests a role as a peptidergic neurotransmitter. The origin and importance of VIP in the circulation is thus uncertain and it may conceivably be merely an overflow of VIP acting locally in various tissues. The plasma concentration may thus reflect the sum of a wide variety of different activities in different organs.

This work was dependent on pure porcine and chicken VIP which was supplied by Professor V. Mutt, Stockholm, and synthetic VIP fragments which were supplied by Professor Yanihara, Japan, for which we are most grateful. The work was supported by the Wellcome Trust and Medical Research Council.
References


